Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials.

ABSTRACT:

Background

Migraine is one of the most common neurological diseases around the world and calcitonin gene-related peptide (CGRP) plays an important role in its pathophysiology. Therefore, in the present study, we evaluated the efficacy of monoclonal antibodies blocking the CGRP ligand or receptor in episodic and chronic migraine.

Objective

The objective of our study is implementing a meta-analysis to systematically evaluate the efficacy and safety of eptinezumab for the treatment of migraine compared with placebo.

Method

We searched the Medline, Embase, Cochrane Library and Clinicaltrials.gov for randomized controlled trials (RCTs) which were performed to evaluate eptinezumab versus placebo for migraine up to September 2020. The data was assessed by Review Manager 5.3

SUBMITTER: Yan Z 

PROVIDER: S-EPMC7937260 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature